Purpose: The lifespan of maintenance hemodialysis patients is reduced mainly because of cardiovascular complications due to accelerated atherosclerosis and impaired angiogenesis. We aimed to compare the effect of unfractionated heparin (UFH) and enoxaparin used as anticoagulants during hemodialysis (HD) on circulating levels of heparin-binding, anti-angiogenic Endostatin, pro-inflammatory RANTES (Regulated upon Activation, Normal T cell Expressed and Secreted), and MCP-1 (Monocyte Chemoattractant Protein-1). Methods: We enrolled 22 chronic HD patients, who were randomly assigned to either enoxaparin (n=11) or UFH (n=11) anticoagulation, and followed prospectively for 12 weeks before crossing over to the alternate therapy for further 12 weeks. The factors were measured (ELISA) at the start, 10 and 180 min of HD, and compared to 20 healthy volunteers. Results: The baseline Endostatin, RANTES, and MCP-1 levels in patients were higher than in controls and comparable during enoxaparin and UFH treatment. RANTES significantly increased during both enoxaparin and UFH anticoagulated HD, while over-HD Endostatin and MCP-1 levels remained stable regardless of the heparin sort. About 25% RANTES increase after 10 min of HD positively correlated with the dose of both heparins and HD duration. The switch from enoxaparin to UFH treatment had no impact on the levels of parameters studied. Patients with ischemic heart disease had less RANTES increase after 180 min of HD especially during enoxaparin treatment. Conclusion: RANTES is dose-depended and transitory increased in response to both UFH and enoxaparin administration during HD. Cardiovascular disease status occurred to be the most important predictor of its over-HD level.
INTRODUCTION
The pathogenesis of the aggressive vascular morbidity and mortality in chronic hemodialysis (HD) patients is unknown but believed to be multi-factorial in origin. As traditional risk factors cannot alone explain the unacceptable high prevalence and incidence of cardiovascular disease (CVD) in this high-risk population, inflammation (interrelated to insulin resistance, oxidative stress, hyperhomocysteinaemia, wasting, and endothelial dysfunction) has been suggested to be a significant contributor [1] . Nowadays it is obvious, that atherosclerosis, which typically occurred in HD patients, presents as an inflammatory disease of the vessel wall. Simultaneously, it has been confirmed that in end stage renal disease vascular repair is defective [2] [3] [4] [5] [6] . Capillary deficiency, especially in the ischemic myocardium, could explain reduced ischemic tolerance in uremia, as evidenced by higher frequency of myocardial infarction in this population [3] . Risk factors that could contribute to understanding of vascular pathology include markers of inflammation as well as pro-and anti-angiogenic factors [7] .
It is generally recognized now that atherosclerosis belongs to the group of chronic diseases in which over-recruitment of leukocytes, especially macrophages and T-cells, is a cornerstone of the pathology [8] . In leukocyte trafficking and activation a subfamily of structurally related, heparin-binding chemokines (CC-chemokines, β-chemokines) are involved. Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) and Regulated upon Activation, Normal T cell Expressed and Secreted (RANTES/CCL5) are the two major members of the CC-chemokines subfamily. The roles of RANTES and MCP-1 are emerging in regulating the mobilization of inflammatory cells into tissue during inflammation [9] . Their production is stimulated by a variety of agents, including the pro-inflammatory cytokines (e.g. IL1, IL6, TNF-α), bacterial lipopolysaccharide and mitogens. In recent years, it has become clear that the function of chemokines extends beyond the role in leukocytes chemotaxis. They participate in organ development, angiogenesis/angiostasis, tumorigenesis and metastasis, heart diseases, as well as in immune response to microbial infection [10] . RANTES, the antibacterial and antiviral protein of 8-34 kDa is produced mainly by T-cells in human atherosclerotic plaque. MCP-1 (30 kDa) is produced by several cell types including endothelium and fibroblasts, and exerts pro-angiogenic function dealing with promotion of endothelial cells proliferation and capacity to form vessels [11, 12] . Both of them combine the ability for interaction with heparin [8] -a forefront anticoagulant administered during blood purification procedures.
Endostatin (ES), also known as antitumor, anti-migration, and anti-permeability factor, presents to be heparin-binding 20 kDa C-terminal fragment of collagen type 18. Collagen type 18 is found in vessel wall and basement membrane [13] . Endostatin specifically inhibits proliferation of endothelial cells and potently inhibits angiogenesis. Its anti-angiogenic activity mainly depends on interaction with heparan sulfate, and thus heparin may release ES from vascular wall [14] . Endostatin may interfere with the pro-angiogenic action of growth factors such as basic fibroblast growth factor (bFGF/ FGF-2) and vascular endothelial growth factor (VEGF).
A number of physiological effects have been ascribed to heparin, many of which are independent of its well characterized activity as an anticoagulant [15] . Nowadays is obvious, that heparins constitute a heterogenous group with different extra-and anticoagulant properties [16, 17] . Chronically HD patients constitute an unusual group because of their repeated and prolonged exposure to heparins during renal-replacement therapy. Therefore, the aim of our study was to compare the effect of standard unfractionated (UFH) and low molecular weight (LMWH-enoxaparin) heparin used as anticoagulants during HD on circulating levels of heparinbinding, anti-angiogenic ES, pro-inflammatory RANTES and pro-angiogenic MCP-1.
MATERIAL AND METHODS

Patients
We enrolled 22 patients (Tab. 1) who were undergoing maintenance HD for a median period of 38.5 (range 4.0 -111) months. End-stage renal failure was attributed to glomerulonephritis (n = 6), interstitial nephritis (n = 5), diabetic nephropathy (n = 3), polycystic kidney disease (n = 1), hypertensive nephropathy (n = 1), secondary amyloidosis (n = 2), acute renal failure (n = 1), and unknown (n = 3). None of the patients received steroids, other immunosuppressive agents, oral anticoagulants, contraceptive drugs, was positive for HIV 1/2 and hepatitis C/B and had an evidence of bacterial and/or viral infection at least 1 month prior to the study. The CRP value was below 6 mg/l at the blood collection moment in each case. Eleven (50%) patients had previously diagnosed ischemic heart disease (IHD) class I-II according to Canadian Cardiovascular Society classification, based on one or more of typical clinical symptoms with prior ECG changes or positive exercise ECG test or past cardiac infarct, alone or in combination. In each case the confirmation of IHD with coronarography was performed. All the patients received erythropoietin. None of them had suffered from any neoplasmatic and pulmonary disease prior and during the study.
The patients were dialyzed for 4 to 5 hours three times weekly using the double-needle technique, native arteriovenous fistulas, standard bicarbonate buffer, low-flux modified cellulose dialyzers, and machines with controlled ultrafiltration. Before each HD session, the extracorporeal circuit was rinsed with 1 000 ml of 0.9% saline containing 2.0 IU/ml of UFH (Heparin; Biochemie, Kundl, Austria). Prior to the study all the patients had been anticoagulated with enoxaparin (Clexane®, Bellon Rhône-Poulenc Rorer, Montrouge, France) during HD session.
Study Protocol
The study was performed in conformity with the Helsinki Declaration. Ethics committee approval was obtained and informed consent was sought from each patient.
The study lasted 6 months. Twenty two patients were randomly assigned to UFH (n = 11) or LMWH (n = 11) anticoagulated HD for 3 months; then the patients were switched to another heparin for the next 3 months. The anticoagulation regiments were: UFH-a bolus of 1 500 (500-3 500) IU into the arterial line followed by an infusion of 2 750 (1 500-6 500) IU via syringe pomp; LMWH enoxaparin-a single dose of 40 (20 -60) mg via the first-access needle at the onset of HD.
The total dose of UFH was 4 840 ± 1 880 IU (66.1 ± 19.2 IU/kg) per HD session. The infusion was started just after the bolus, and stopped 1 hour before the end of HD. The UFH dosage had been individually titrated on the basis of whole blood activated partial thromboplastin time (WBAPTT) and established during the first 3 sessions after randomization. The goal was to obtain a twofold prolongation of WBAPTT at both 30 and 120 minutes of HD compared with the baseline value.
The effective dose of enoxaparin was 0.67 ± 0.14 mg/kg (1 mg = 100 IU of antifactor Xa). It was established on the basis of the following clinical guidelines: no visible fibrin clots in the arterial and venous bubble traps during HD, no clotted filters after HD, and no bleeding from the fistula puncture sites after compression [18] . Clinical clotting was evaluated by nursing stuff by visual inspection after blood draining of the air trap every hour (1 = no clotting in the trap, 2 = fibrous ring, 3 = clot formation and 4 = coagulated system) and by visual inspection of the dialyser at the middle and at the end of each session (1 = clean filter, 2 = a few blood stripes /affecting less than 5% of the fibers seen at the surface of the dialyser/, 3 = many blood stripes /affecting more than 5% of the fibers/, and 4 = coagulated filter).
After 3 months since the randomization procedure, plasma RANTES, MCP-1, and ES levels were measured predialysis (T 0 ), at 10 min (T 10 ) and 180 min (T 180 ) after beginning of HD session in the patients anticoagulated with either UFH or LMWH. The measurements were next repeated after the further 3 months since the heparin switch. Each patient was tested against him/herself.
The study was designed to keep the heparin doses, other HD prescriptions and pharmacologic treatment stable during the follow-up. All the patients uneventfully completed the study.
Laboratory Procedures
Fasting blood was drawn without use of a tourniquet through a wide-gauge butterfly needle into monovettes containing a 1.2 ml EDTA (ethylenediaminotetraacetic acid). In each case blood was obtained during a midweek morning HD session: at T 0 from the arterial needle (before heparinization), and at T 10 and T 180 from the predialyzer port after slowing the blood flow to 100 ml/min for 1 min. The first 1 ml of blood was discarded; then 4.5 ml of blood was collected. Tubes were placed in melting ice and centrifuged 15 min later at 2 000 g for 30 min. One third of the plasma was collected from middle region of the supernatant, aliquoted, and immediately frozen at-80 o C. Batch analyses were performed within 8 weeks. Plasma RANTES and ES antigen levels were determined using solid-phase enzyme-linked immunosorbent assays (ELISA) kits purchased from R&D Systems, Inc., Minneapolis, MN, USA (Quantikine ® ). For quantitative detection of plasma MCP-1 antigen enzyme immunoassay kit purchased from IBL, Hamburg, Germany was used. The assays quantify human-specific factors and their mean minimum detectable levels were 2.0 ng/ml, 0.023 µg/ml, and 2.31 pg/ml, respectively. All the measurements were performed in duplicate using a 400 SFC photometer (SLT-Labinstruments, Gröding/ Salzburg, Austria), and calibrated using provided recombinant human reference samples and standards. For calculation of the results, a computer and a curve-fitting program were used. The within-and between-assays coefficients of variations were < 10%. The T 180 values were corrected for hemoconcentration according to serum albumin levels. WBAPTT was measured using an automated coagulation system and reagents from BioMérieux (Marcy-I'Etoile, France).
Statistical Analysis
Shapiro-Wilk's W test of normality was used for data distribution analysis. The normally distributed data were presented as mean ± 1 SD, and the skewed data as median (full range). The antigens' plasma levels comparison between patients with-and without IHD was tested with nonparametric Mann-Whitney's U-test. Intragroup comparisons were performed with nonparametric Friedman's ANOVA by ranks and Wilcoxon's single-rank tests. Bivariate correlations were assessed using nonparametric Spearman's regression analysis. For multiple regression analysis Hierarchical Multiple model was used. All statistical tests were two-sided, and P < 0.05 was considered significant. Statistica software (version 9.0 PL, StatSoft, Tulsa, OK, USA) was used.
RESULTS
Baseline RANTES, ES and MCP-1 levels in controls and HD patients
All the parameters studied were significantly higher in maintenance HD patients than in controls, regardless of the sort of heparin used (all P < 0.005, Tab. 2).
Pre-dialysis plasma RANTES, ES and MCP-1 levels were comparable during enoxaparin and UFH treatment (all P > 0.05; Tab. 2, Fig. 1 ).
RANTES during LMWH and UFH hemodialysis
Plasma RANTES levels significantly changed over both enoxaparin (χ 2 ANOVA = 14.18, P < 10 During enoxaparin treatment they increased by a mean of 26.5 % after 10 min (P = 0.002) and remained still elevated by a mean of 24.8 % after 180 min (P = 0.01) of the session compared to the pre-HD values. RANTES increment after 180 min of HD positively correlated with the enoxaparin dosage per kg of body weight (r = 0.454, P = 0.033, Fig.  2A ) and HD therapy duration (r = 0.594, P = 0.004) and were the highest in patients without IHD (IHD vs. non IHD patients P = 0.004, Tab. 3). Interestingly, patients with IHD under enoxaparin treatment did not show any significant intra-dialysis RANTES changes (Tab. 3). According to the regression analysis, presence of IHD occurred to be an independent negative predictor of RANTES increase after 180 min of HD (Tab. 4).
During UFH anticoagulated HD plasma RANTES levels increased by a mean of 23.4% after 10 min (P = 0.001) and remained elevated by a mean of 18.6% after 180 min (P = 0.027) of HD compared to the baseline values. The chemokine increase after 180 min was positively correlated with total UFH dosage per kg of body weight (r = 0.442, P = 0.039; Fig. 2B ) and was lower compared to enoxaparin treatment regardless of IHD presence (Tab. 3).
We did not observe any associations between RANTES levels after both 10 and 180 min and appropriate white blood cell and lymphocytes count (all P >0.05). Also, there were no significant associations between RANTES levels and HD parameters: dialysis dose (Kt/V), ultrafiltration volume or surface area of the dialyzers (all P >0.05). Also, we did not find any correlation between plasma RANTES levels and MCP-1 as well as ES over-HD values.
MCP-1 during LMWH and UFH hemodialysis
Plasma MCP-1 levels remained stable during both enoxaparin 
Endostatin during LMWH and UFH hemodialysis
Over-HD plasma ES levels did not changes during enoxaparin (χ 2 ANOVA = 1.18, P = 0.554; Tab. 2, Fig. 1D ) as well as UFH (χ 2 ANOVA = 1.73, P = 0.422; Tab. 2, Fig. 1C ) treatment.
The effect of heparin switch
The switch from enoxaparin to UFH treatment had no impact on overall RANTES, MCP-1 and ES levels in any period of the study (Tab. 2, Fig. 1A-F) . However, in patients without IHD anticoagulated with enoxaparin, it was connected with significant higher plasma RANTES increase after 180 min of HD session (Tab. 3).
DISCUSSION
The novel finding of this study is a significant plasma RANTES increase during HD procedure in response to LMWH-enoxaparin and UFH administration. Interestingly, this increment after 180 min of HD was more pronounced in patients without ischemic heart disease. Simultaneously, the purification procedure had no impact on pro-angiogenic MCP-1 and anti-angiogenic ES levels regardless of the sort of heparin used. 
RANTES -Regulated upon Activation, Normal T cell Expressed and Secreted; MCP-1 -Monocyte Chemoattractant Protein-1; ES -Endostatin; UFH -unfractionated heparin; HD -hemodialysis Delta denotes plasma RANTES changes after 180 min of HD compared with baseline values.
Our data showed higher pre-dialysis RANTES levels in maintenance HD patients compared to the healthy subjects. Their mean values amount to 72 ng/ml that is almost as high as in patients with breast cancer [19] . In contrast, previous studies by Pawlak et al. [20, 21] showed lower pre-HD RANTES levels in relation to the healthy controls. The reasons for this discrepancy may be dual: 1) considerable intra-and inter-individual variability; 2) differences in laboratory assessment. According to Boenisch et al. [22] who studied individual patterns of several inflammatory markers measured weekly for 12 weeks in HD patients, intraindividual differences were largest for plasma RANTES values (coefficient of variations about 80%). On that ground, to identify patients with high cardiovascular risk, they strongly recommend repeated measurements for RANTES and other acute phase proteins even in patients with no apparent signs of infection. Even though RANTES is well known independent risk predictor of short-term mortality in patients with e.g. acute coronary syndromes [23] its usefulness in renal replacement therapy is doubtful. For example, Péquériaux and colleagues have recently revealed that plasma RANTES concentration cannot be used as a predictor of mortality in chronic hemodialysis patients [24] . Our findings concerning a positive correlation between over-HD RANTES levels and heparin dose as well as HD duration can support Péquériaux's observation. All these facts indicate that RANTES concentration in HD patients can be modified by factors related to renal replacement therapy itself, especially extracorporeal procedure such as HD session.
Over-dialysis plasma RANTES increment noticed in our patients, regardless of the heparin sort, could be initiated by extracorporeal leukocyte activation. However, there was no correlation between RANTES and e.g. leukocytes count, what support previous investigations [25] . According to our study the most important predictor of plasma RANTES increment after 180 min of dialysis session was patients' IHD status. Patients with ischemic heart disease had lower intradialysis RANTES increase especially during enoxaparin treatment. The reason(s) for this phenomenon is actually unclear. Hariharan et al. [26] reported that RANTES is secreted mainly by CD45RO+ cells in adult (peripheral) blood lymphocytes. However we did not observe any correlation between plasma RANTES levels and lymphocyte counts.
Simultaneously, there were no differences in lymphocytosis between our positive and negative IHD status patients (data not shown). Thus, observed in our study intra-dialysis RANTES increase is probably mainly connected with heparin binding effect. Strong, positive correlation between this increment and heparin dose can affirm this remark. Still, enoxaparin advantage over UFH in this phenomenon remains difficult to explain.
Our study confirms also the previous reports about remarkably high ES [27] and MCP-1 [20, 21, 28 ] levels in HD patients compared to the healthy control group. In the respect that the progression of atherosclerosis is accelerated and angiogenesis is impaired in chronic kidney diseases, especially in its end-stage, the issue seems to be of special significance [29, 30] . Nowadays it is still unknown, if this increment is caused by the uremic environment or by hypoxia itself [31] . According to our findings and that of Seko et al. [32] it seems rather obvious that it is not due to heparin administration. Abundance of both inhibitors and stimulants of neo/angiogenesis in uremic plasma may reflect complete disruption of vascular regeneration and repair controlling process, which contribute to acceleration of cardiovascular diseases. In contrast to Pawlak et al. [20] , pre-dialysis MCP-1 levels in our patients with ischemic heart disease did not differ from patients without IHD. However, after 180 min of HD, especially under enoxaparin treatment, MCP-1 values in IHD group were higher compared to non-IHD subjects. Considering the lack of any correlations between MCP-1 levels and heparins' dosages we connected this observation rather with hemoconcentration effect.
CONCLUSIONS
RANTES is dose-depended and transitory increased in response to both UFH and enoxaparin administration during HD procedure. Cardiovascular disease status occurred to be very potent predictor of its over-HD level. Unusually high ES and MCP-1 plasma levels in chronic HD patients and the significance of this observation, in spite of numerous previous reports, remain still unclear and inexplicable. 
